BAP1 and metastatic neoplasm: Germline BAP1 mutation appeared to result in more metastatic disease compared to non-BAP1 carriers (71.4% vs. 18.0%) in a small comparison between 7 germline BAP1 UM and 455 UM without germline BAP1 [75].